ArticleCureus2026
Unequal Burdens: Exploring Racial Differences in Sarcoidosis-Related Deaths Due to Pulmonary Hypertension Versus Fibrosis in the United States (1999-2023).
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Sarcoidosis disproportionately affects Black Americans, who report a higher incidence (17.8 per 100,000) compared to White Americans (8.1 per 100,000) and also experience greater disease severity, leading to an overall worse prognosis. Despite these trends, racial differences in cause-specific mortality among patients with sarcoidosis remain unexplored. In light of this, we aimed to assess longitudinal trends in mortality rates attributed to pulmonary causes of death among individuals with comorbid sarcoidosis. Methods We conducted a retrospective repeated cross-sectional study to determine the cause of death attributed to pulmonary deaths with comorbid sarcoidosis in the United States from 1999 to 2023. The data were obtained from the Centers for Disease Control and Prevention's Wide Ranging Online Data for Epidemiologic Research (CDC WONDER) database, which includes the underlying and contributing causes of death from all death certificates in the United States. Results Of the 24,156 pulmonary deaths with comorbid sarcoidosis identified, 61.1% were women, and nearly 50% were aged 55-74 years. The age-adjusted mortality rate (AAMR) increased from 2.7 (95% confidence interval (CI): 2.5-3.0) per million in 1999 to 4.8 (95% CI: 4.5-5.1) in 2023. The annual percentage change (APC) was +1.1% (95% CI: 0.85-1.35) from 2001 to 2018, with a marked rise from 2018 to 2020 (APC: +10.36%, 95% CI: 4.50-16.54). Pulmonary fibrosis (PF) and pulmonary hypertension (PH) constituted 70% of pulmonary deaths with sarcoidosis. When stratified by race, Black individuals are more likely to die from PH (37.3%), with a greater burden in Black women (40.5%). In contrast, White individuals most commonly died from pulmonary fibrosis (PF) (52.8%). Conclusions Pulmonary deaths in sarcoidosis have increased over the past two decades, with racial disparities evident in underlying phenotypes. Black individuals, especially Black women, are more likely to die from PH, while White individuals disproportionately die from fibrosis. These findings highlight the importance of phenotype-specific screening strategies and equity-focused clinical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.